AUROPHARMA Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > auropharma

Technical Analysis

Technical Strength: 1.3 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 36.9. According to RSI analysis, auropharma is technically weak. 1.0 AUROPHARMA RSI Chart
MACD (?) MACD: -9.79 and Signal Line: -7.89. According to MACD analysis, auropharma is technically weak. 2.0 AUROPHARMA MACD Chart
Simple Moving Average (?) 50-day simple moving average just got below it's 200-day simple moving average which is a negative signal. According to simple moving average analysis, auropharma is in a strong downtrend. Major resistance levels are 671.91, 685.55, 686.4462. 0.0 AUROPHARMA Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, auropharma is in a strong downtrend. Major resistance levels are 668.318, 685.613, 699.0915. 0.0 AUROPHARMA Exponential Moving Average Chart
Bollinger Bands (?) %b is -0.00288. According to bollinger bands, auropharma has hit the lower band which is a negative signal. 1.0 AUROPHARMA Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is below all levels. Resistance levels are 659.7777 and 667.725. Support level is 634.05. 2.5 AUROPHARMA Fibonacci Retracement Chart
Average True Range (?) ATR: 16.9 NA AUROPHARMA Average True Range Chart
Average Directional Index (?) ADX is 18.6 which means AUROPHARMA is in a trading range and there is no trend. NA AUROPHARMA Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
January 18, 2018
Open Price 657.0
High Price 663.75
Low Price 639.0
Close Price 645.85
Absolute Change -11.4
Percentage Change -1.73%
Weekly Change -4.25%
Monthly Change -6.09%
Yearly Change -8.32%
52-week high 809.45
52-week low 503.05
Corporate Actions
ExDate Purpose
November 21, 2017 INT DIV RS 1.50 PER SHARE
August 23, 2017 ANNUAL GENERAL MEETING
June 08, 2017 INT DIV RS 1.25 PER SHARE
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)1.17
Confidence in Beta2.5%
Market Capital Rs. 37718.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 20.9771875
TTM Price-to-Earnings (P/E) Ratio 30.8
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 18 January 2018: Deliverable Quantity:1.25e+06 NA AUROPHARMA Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 18 January 2018: Daily Volatility:0.2866 NA AUROPHARMA Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 18 January 2018: PCR_OI:0.424 PCR:0.416 NA AUROPHARMA PCR Chart
Option Pain (?) 18 January 2018: Max Pain:680.0 NA AUROPHARMA Option Pain Chart
Premium (?) 18 January 2018 Premium: 0.45 Futures OI:23364800.0 NA AUROPHARMA Premium Chart
Option_MAX_OI (?) 18 January 2018: Price:645.85 Put with maximum OI:660.0 Call with maximum OI:700.0 NA AUROPHARMA Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
January 25, 2018 646.3 23364800.0 6620.0 7219.0 645.85
February 22, 2018 649.6 2002400.0 1325.0 1508.0 645.85
March 28, 2018 652.35 82400.0 28.0 30.0 645.85

Announcements

January 09, 2018 Investor Presentation Aurobindo Pharma Limited has informed the Exchange regarding Investor Presentation
December 27, 2017 Press Release Aurobindo Pharma Limited has informed the Exchange regarding a press release dated December 27, 2017, titled "Aurobindo Pharma receives USFDA Approval for Fondaparinux Sodium Injection".
See all Announcements

Board Meetings

Date Meeting Date Purpose
October 31, 2017 November 09, 2017 Results/Dividend to consider and approve, inter alia, the Un-audited Financial results of the Company for the second quarter and half year ended September 30, 2017 and also to consider interim dividend, if any, for the financial year 2017-18.
July 27, 2017 August 09, 2017 Results To consider and approve, inter alia, the Un-audited Financial Results of the Company for the first quarter ended June 30, 2017.
See all Board Meetings

AUROPHARMA is part of...

Index Weightage
NIFTY NA
CNXPHARMA NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 610.6 Rs. 624.8 Rs. 635.3 Rs. 649.5 Rs. 660.1 Rs. 674.3 Rs. 684.8